Cody Peer

Cody J. Peer, Ph.D., M.S.

  • Center for Cancer Research
  • National Cancer Institute


Cody Peer is a pharmacometrician and pharmacologist specializing in pharmacokinetic (PK) and pharmacometric (exposure-response) modeling and simulation. As Deputy Head of the Clinical Pharmacology Program (CPP). Dr. Peer leads a team whose mission is to fully characterize the clinical pharmacology of new anticancer agents entering the CCR clinics. The CPP also provides biospecimen collection and processing, bioanalytical support, and clinical trial design.

Areas of Expertise

1) pharmacokinetics 2) pharmacometrics 3) clinical trial design 4) bioanalytical assay validation


Selected Recent Publications

Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation

Peer CJ, Heiss BL, Goldstein DA, Goodell JC, Figg WD, Ratain MJ.
J Clin Pharmacol. 62(4): 532-540, 2022. [ Journal Article ]

Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors

Peer CJ, Goldstein DA, Goodell JC, Nguyen R, Figg WD, Ratain MJ.
Br J Clin Pharmacol. 86(9): 1769-1777, 2020. [ Journal Article ]

Selumetinib in Children with Inoperable Plexiform Neurofibromas

Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, Widemann BC.
N Engl J Med. 383(13): 1290, 2020. [ Journal Article ]

A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer

Peer CJ, Schmidt KT, Kindrick JD, Eisner JR, Brown VV, Baskin-Bey E, Madan R, Figg WD.
Cancer Chemother Pharmacol. 84(4): 759-770, 2019. [ Journal Article ]

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.
J Clin Oncol. 36(14): 1389-1395, 2018. [ Journal Article ]


Postdoctoral Fellow (Visiting)
Tobi Arisa, Ph.D.
Postbaccalaureate Fellow
Natalia Corvalan, B.S.
Postbaccalaureate Fellow
Annieka Reno, B.S.
Postbaccalaureate Fellow
Will Richardson, B.S.